Earlier this year, the company had reported on the favorable pharmacokinetic profile of the drug showing enhanced bioavailability of the Pro-drug PPL-100 (compared to parent drug, PL-100) and suggesting the utility of the drug administered as a potential once daily regimen.
Previous reports have also shown PPL-100 to have a unique cross- resistance profile compared to other commercially available HIV protease inhibitors.
“We are pleased with the solid safety profile of our PPL-100 HIV protease inhibitor as this is a critical issue in the development of such compounds,” said Hans Mader, president and CEO of Procyon Biopharma. “Together with the favorable cross-resistance profile, increased bioavailability through the Pro-drug approach, we believe PPL-100 to be a very promising therapy for the treatment of HIV-infection and we are on track to begin clinical trials by year end,” he concluded.